CD22 CD22 molecule

For inotuzumab ozogamicin, epratuzumab, bectumomab, inotuzumab, yttrium y 90 epratuzumab tetraxetan, BL22, pinatuzumab vedotin, yttrium y 90 epratuzumab, epratuzumab-cys-tesirine, mono-dga-rfb4: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.

• FDA pediatric target list: yes · CD22 is on the list. Membership alone neither requires nor waives a pediatric study.

  Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
• EU paediatric investigation plan: yes · EMEA-001429-PIP01-13-M07 (Inotuzumab ozogamicin, Treatment of B cell acute lymphoblastic leukaemia): PM: decision on the application for modification of an agreed PIP, 10 Mar 2023; EMEA-001295-PIP01-12-M01 (Epratuzumab, Treatment of Systemic Lupus Erythematosus (SLE)): PM: decision on the application for modification of an agreed PIP, 5 Jun 2015

  Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
• EU orphan designation: yes · EU/3/13/1127 positive 7 Jun 2013: Treatment of B-cell acute lymphoblastic leukaemia

  Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA EU/3/13/1127, 2026-11-11
• Authorised in the EU: yes · Besponsa: authorised since 28 Jun 2017, orphan medicine

  Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Besponsa, 2026-11-11
• FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link

  Rule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
• FDA pediatric oncology approval: yes · Inotuzumab ozogamicin [Besponsa], 6 Mar 2024: Treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older

  Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
• Registered studies open to children: yes · 33 interventional studies of inotuzumab ozogamicin, epratuzumab, bectumomab, inotuzumab, yttrium y 90 epratuzumab tetraxetan, bl22, pinatuzumab vedotin, yttrium y 90 epratuzumab, epratuzumab-cys-tesirine, mono-dga-rfb4 include patients under 18; 17 are recruiting, not yet recruiting or active

  Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11

Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.